

LFC Requester:

Eric Chenier

**AGENCY BILL ANALYSIS
2025 REGULAR SESSION**

WITHIN 24 HOURS OF BILL POSTING, UPLOAD ANALYSIS TO:

Analysis.nmlegis.gov

{Analysis must be uploaded as a PDF}

SECTION I: GENERAL INFORMATION

{Indicate if analysis is on an original bill, amendment, substitute or a correction of a previous bill}

Check all that apply:

Original **Amendment**
Correction **Substitute**

Date 1-31-2025

Bill No: SB 207

Sponsor: Sens. Elizabeth "Liz" Stefanics
and Elizabeth "Liz" Thomson
Short Title: ADD CLASSES TO PRIOR
AUTHORIZATION FORM

**Agency Name
and Code
Number:** Regulation and Licensing
Department - 420

Person Writing Jen Rodriguez
Phone: 505-795-3250 **Email** Jen.rodriguez@rld.nm.gov

SECTION II: FISCAL IMPACT

APPROPRIATION (dollars in thousands)

Appropriation		Recurring or Nonrecurring	Fund Affected
FY25	FY26		
N/A	N/A	N/A	N/A

(Parenthesis () Indicate Expenditure Decreases)

REVENUE (dollars in thousands)

Estimated Revenue			Recurring or Nonrecurring	Fund Affected
FY25	FY26	FY27		
N/A	N/A	N/A	N/A	N/A

(Parenthesis () Indicate Expenditure Decreases)

ESTIMATED ADDITIONAL OPERATING BUDGET IMPACT (dollars in thousands)

	FY25	FY26	FY27	3 Year Total Cost	Recurring or Nonrecurring	Fund Affected
Total	N/A	N/A	N/A	N/A	N/A	N/A

(Parenthesis () Indicate Expenditure Decreases)

Duplicates/Conflicts with/Companion to/Relates to:
Duplicates/Relates to Appropriation in the General Appropriation Act

SECTION III: NARRATIVE

BILL SUMMARY

Synopsis: Senate Bill 207 (SB207)

SB207 bars insurance companies from requiring prior authorization for medications prescribed for off-label or on-label usage for the treatment of an autoimmune disorder, cancer, a rare disease or substance disorder.

SB207 would also stop insurance companies from requiring prior authorization or “step-therapy” — meaning, proving to insurance companies that a patient tried all other available treatments prior to agreeing to pay for the medication or treatment in question — for rare diseases.

SB207 further defines rare diseases for the purpose of this section as a disease or medical condition that affects fewer than two hundred thousand (200, 000) people in the United States.

FISCAL IMPLICATIONS

The Regulation and Licensing Department does not anticipate any significant fiscal impact from the enactment of SB207.

SIGNIFICANT ISSUES

PERFORMANCE IMPLICATIONS

ADMINISTRATIVE IMPLICATIONS

CONFLICT, DUPLICATION, COMPANIONSHIP, RELATIONSHIP

TECHNICAL ISSUES

OTHER SUBSTANTIVE ISSUES

ALTERNATIVES

WHAT WILL BE THE CONSEQUENCES OF NOT ENACTING THIS BILL

AMENDMENTS